Detalles de la búsqueda
1.
Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Jpn J Clin Oncol
; 52(12): 1430-1435, 2022 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36093731
2.
Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study.
Anticancer Drugs
; 31(3): 298-303, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31913197
3.
Predictive factors of late biochemical recurrence after radical prostatectomy.
Jpn J Clin Oncol
; 47(3): 233-238, 2017 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27940489
4.
Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
Anticancer Res
; 44(4): 1675-1681, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537962
5.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Curr Oncol
; 31(2): 862-871, 2024 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38392058
6.
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Anticancer Res
; 43(12): 5689-5698, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38030199
7.
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Anticancer Res
; 43(10): 4701-4708, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772560
8.
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
Anticancer Res
; 42(3): 1571-1577, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35220254
9.
External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy.
JMA J
; 5(2): 224-229, 2022 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35611227
10.
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Cancer Manag Res
; 14: 1641-1651, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35535266
11.
Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Clin Genitourin Cancer
; 20(5): 499.e1-499.e8, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35624001
12.
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Onco Targets Ther
; 15: 1321-1330, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36388155
13.
Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma.
Mol Clin Oncol
; 14(5): 91, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33767860
14.
Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
In Vivo
; 35(5): 2869-2874, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34410980
15.
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Cancer Manag Res
; 13: 8049-8056, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34729023
16.
Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy.
Onco Targets Ther
; 14: 1981-1988, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33776447
17.
Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study.
Prostate Int
; 9(2): 96-100, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34386452
18.
Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Anticancer Res
; 41(3): 1539-1545, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33788747
19.
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
J Clin Med Res
; 12(5): 300-306, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32489505
20.
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Anticancer Res
; 40(1): 335-339, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31892584